[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-453091-105":59,"doc-detail-453091-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","from-plaques-to-pigment-eruptive-lentiginosis-in-resolving-psoriatic-plaques-after-biologic-therapy","From plaques to pigment - Eruptive lentiginosis in resolving psoriatic plaques after biologic therapy","","Case series describing eruptive lentiginosis arising in areas of resolving psoriatic plaques (ELRP) after biologic therapy for psoriasis. The article notes ELRP as a rare phenomenon first reported in 1994 and increasingly linked to biologic agents, particularly interleukin-17A and interleukin-23 inhibitors. Six ELRP cases are presented, highlighting clinical presentation as hyperpigmented patches with lentigines at prior plaque sites, diagnostic context through physical examination, and treatment timelines including biologic initiation and subsequent clearance or improvement patterns. A literature review is conducted to identify potential risk factors after starting biologic psoriasis treatment.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/from-plaques-to-pigment-eruptive-lentiginosis-in-resolving-psoriatic-plaques-after-biologic-therapy/453091/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/from-plaques-to-pigment-eruptive-lentiginosis-in-resolving-psoriatic-plaques-after-biologic-therapy/453091.png","ImageObject",300,407,{"name":92,"@type":93},"Lucas Martin","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is eruptive lentiginosis in areas of resolving psoriatic plaques (ELRP)?","Question",{"text":112,"@type":113},"ELRP is a rare phenomenon where eruptive lentiginosis develops in regions where psoriatic plaques are resolving after psoriasis treatment. The paper focuses on ELRP occurring after biologic therapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which biologic therapies are implicated in these ELRP cases?",{"text":117,"@type":113},"The six presented cases occurred after treatment with either an interleukin (IL)-17A inhibitor or an IL-23 inhibitor. The introduction also discusses broader associations with psoriasis treatments.",{"name":119,"@type":110,"acceptedAnswer":120},"How does ELRP typically look on physical examination?",{"text":121,"@type":113},"Physical examination shows faint or hyperpigmented patches at sites of prior psoriatic plaques, with multiple small light to dark brown macules consistent with lentigines.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},453091,1790764127,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","CASE SERIES  \nFrom plaques to pigment: Eruptive lentiginosis in resolving psoriatic plaques after biologic therapy  \nSarah Choe, MD,a ,b Aneri Bhargav Patel, BS,a ,c Celine Phong, MD,a Katerina Yale, MD,a Nicole M. Golbari, MD, MPH,d Christopher B. Zachary, MBBS,a and Michelle S. Min, MD, MSa  \nKey words: biologic therapy; hyperpigmentation; lentigines; psoriasis.  \nINTRODUCTION  \nEruptive lentiginosis arising in areas of resolving psoriatic plaques (ELRP) is a rare phenomenon, first described in 1994 following treatment with ultraviolet A phototherapy.1,2 Since this initial report, subsequent cases have emerged in association with various therapeutic modalities for psoriasis, including topical corticosteroids, calcipotriol, coal tar solution, oral methotrexate, and apremilast.3 More recently, biologic agents have been implicated in an increasing number of ELRP cases.2,4-9 Herein, we present 6 cases of ELRP following treatment with either an interleukin (IL) − 17A or IL-23 inhibitor. To further understand this phenomenon, a comprehensive literature review was completed to identify potential risk factors for the development of ELRP subsequent to initiation of psoriasis biologic therapy.  \nCASE SERIES  \nCase 1  \nA 51-year-old woman with Fitzpatrick skin type (FST) III and a history of anxiety, hyperlipidemia (HLD), hypertension (HTN), obesity, and psoriatic arthritis (PsA) presented with a 10-year history of severe psoriasis on her scalp, neck, back, abdomen, upper extremities, chest, and thighs. She was on secukinumab (150 mg every 4 weeks), started 1 year prior. Previous treatments included topicals, acitretin,  \nFrom the Department of Dermatology, University of California Irvine School of Medicine, Irvine, Californiaa; California University of Science and Medicine, School of Medicine, Colton, Californiab; University of California, Davis, School of Medicine, Sacramento, Californiac; and Department of Dermatology, New York University Langone Health, New York, New York.d  \nDr Choe and Author Patel contributed equally to this work and should be considered first co-authors.  \nDrs Zachary and Min are senior co-authors for this paper.  \nFunding sources: None.  \nPatient consent: All information has been de-identified to remove direct identifiers, and images do not contain identifiable features. Patient consent was not obtained, as the data have been anonymized following ethical guidelines.  \nAbbreviations used:  \nBSA: body surface area  \nELRP: eruptive lentiginosis in areas of resolving psoriasis plaques  \nFST: fitzpatrick skin type  \nHLD: hyperlipidemia  \nHTN: hypertension  \nIL: interleuki  \nNB-UVB: narrowband ultraviolet B  \nPE: physical examination  \nPsA: psoriatic arthritis  \nnarrowband ultraviolet B (NB-UVB) phototherapy, and adalimumab, all of which provided minimal improvement of psoriatic plaques. Upon initiation of secukinumab, the patient’s psoriasis. On physical examination (PE), faint hyperpigmented patches were observed on bilateral forearms and elbows, corresponding to sites of previous psoriatic plaques. Within the patches, multiple 2-4 mm light brown macules were observed (Fig 1) .  \nCase 2  \nA 62-year-old man with FST II and a history of ankylosing spondylitis presented with a 5-year history of severe psoriasis. The patient also had a history of squamous cell carcinoma in situ of the tongue with subsequent vocal cord paralysis status  \nIRB approval status: Not applicable.  \nCorrespondence to: Michelle Min, MD, MS, Department of Dermatology, 843 Health Sciences Rd, Room 1001, Irvine, CA  \n[92617. E-mail:](92617. E-mail: minms@hs.uci.edu)[ minms@hs.uci.edu](92617. E-mail: minms@hs.uci.edu). JAAD Case Reports 2026;67:216-25.  \n2352-5126  \n© 2025 The Author(s) . Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc. This is an open access article under the CC BY license ([http://creativecommons.org/](http://creativecommons.org/)[ ](http://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/","cbCailN31xrO2pQe","https://ap.wps.com/l/cbCailN31xrO2pQe","pdf",5235911,"English","# Introduction\n# Case series\n## Case 1\n## Case 2\n## Case 3","[{\"question\":\"What is eruptive lentiginosis in areas of resolving psoriatic plaques (ELRP)?\",\"answer\":\"ELRP is a rare phenomenon where eruptive lentiginosis develops in regions where psoriatic plaques are resolving after psoriasis treatment. The paper focuses on ELRP occurring after biologic therapy.\"},{\"question\":\"Which biologic therapies are implicated in these ELRP cases?\",\"answer\":\"The six presented cases occurred after treatment with either an interleukin (IL)-17A inhibitor or an IL-23 inhibitor. The introduction also discusses broader associations with psoriasis treatments.\"},{\"question\":\"How does ELRP typically look on physical examination?\",\"answer\":\"Physical examination shows faint or hyperpigmented patches at sites of prior psoriatic plaques, with multiple small light to dark brown macules consistent with lentigines.\"}]","From plaques to pigment - Eruptive lentiginosis in resolving psoriatic plaques after biologic therapy | PDF",1790738232,25]